Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab extended-interval versus standard-interval dosing in relapsing-remitting multiple sclerosis with SC/IV crossover extension
NL-OMON54587Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of natalizumab in multiple sclerosis (MS) (4 arms), sponsored by Biogen. Primary endpoints: Number of new or newly enlarging T2 hyperintense lesions at Week 72 and Percentage of participants indicating a preference for natalizumab subcutaneous administration at the end of Part 2. Started Jun 2019; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54587.